Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS
- PMID: 20089450
- DOI: 10.1016/j.it.2009.12.003
Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS
Abstract
CD8(+) cytotoxic T lymphocyte (CTL) responses are crucial in establishing the control of persistent virus infections. Population studies of HIV-1-infected individuals suggest that CD8(+) CTL responses targeting epitopes that take the greatest toll on virus replication are instrumental in immune control. A major question for vaccine design is whether incorporating epitopes responsible for controlling a persistent virus will translate into protection from natural infection or serve solely as a fail-safe mechanism to prevent overt disease in infected individuals. Here, we discuss qualitative parameters of the CD8(+) CTL response and mechanisms operative in the control of persistent virus infections and suggest new strategies for design and delivery of HIV vaccines.
Published by Elsevier Ltd.
Similar articles
-
Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.Trends Immunol. 2008 Nov;29(11):574-85. doi: 10.1016/j.it.2008.07.010. Trends Immunol. 2008. PMID: 18838298 Review.
-
New paradigms for generating effective CD8+ T cell responses against HIV-1/AIDS.Discov Med. 2010 Jun;9(49):528-37. Discov Med. 2010. PMID: 20587342
-
Correlates of cytotoxic T-lymphocyte-mediated virus control: implications for immunosuppressive infections and their treatment.Philos Trans R Soc Lond B Biol Sci. 2000 Aug 29;355(1400):1059-70. doi: 10.1098/rstb.2000.0643. Philos Trans R Soc Lond B Biol Sci. 2000. PMID: 11186307 Free PMC article. Review.
-
Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development.Behring Inst Mitt. 1994 Dec;(95):23-34. Behring Inst Mitt. 1994. PMID: 7755506 Review.
-
Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location.J Intern Med. 2009 Jan;265(1):125-37. doi: 10.1111/j.1365-2796.2008.02054.x. J Intern Med. 2009. PMID: 19093965 Review.
Cited by
-
Stem cell-based approaches to treating HIV infection.Curr Opin HIV AIDS. 2011 Jan;6(1):68-73. doi: 10.1097/COH.0b013e3283412370. Curr Opin HIV AIDS. 2011. PMID: 21242896 Free PMC article. Review.
-
GUCY2C-targeted cancer immunotherapy: past, present and future.Immunol Res. 2011 Dec;51(2-3):161-9. doi: 10.1007/s12026-011-8253-7. Immunol Res. 2011. PMID: 22038530 Free PMC article. Review.
-
The role of MHC class I gene products in SIV infection of macaques.Immunogenetics. 2017 Aug;69(8-9):511-519. doi: 10.1007/s00251-017-0997-3. Epub 2017 Jul 10. Immunogenetics. 2017. PMID: 28695289 Free PMC article. Review.
-
IL-2 complex treatment can protect naive mice from bacterial and viral infection.J Immunol. 2010 Dec 1;185(11):6584-90. doi: 10.4049/jimmunol.1001215. Epub 2010 Oct 29. J Immunol. 2010. PMID: 21037095 Free PMC article.
-
Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.Retrovirology. 2015 Nov 19;12:98. doi: 10.1186/s12977-015-0223-z. Retrovirology. 2015. PMID: 26585907 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials